A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. (Q48109352)

8 February 2018

title

A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. (English)

1 reference

8 February 2018

main subject

phase II clinical trial

0 references

0 references

1 reference

Jeffrey J Raizer

1

1 reference

8 February 2018

Sean Grimm

2

1 reference

8 February 2018

Marc C Chamberlain

3

1 reference

8 February 2018

M Kelly Nicholas

4

1 reference

8 February 2018

James P Chandler

5

1 reference

8 February 2018

Kenji Muro

6

1 reference

8 February 2018

Steven Dubner

7

1 reference

8 February 2018

Alfred W Rademaker

8

1 reference

8 February 2018

Jaclyn Renfrow

9

1 reference

8 February 2018

Markus Bredel

10

1 reference

8 February 2018

language of work or name

English

0 references

publication date

1 November 2010

1 reference

8 February 2018

published in

Cancer

1 reference

8 February 2018

volume

116

1 reference

8 February 2018

page(s)

5297-5305

1 reference

8 February 2018

issue

22

1 reference

8 February 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Angiogenesis in brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Salvage therapy with single agent bevacizumab for recurrent glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Direct observation of individual endogenous protein complexes in situ by proximity ligation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Protein detection using proximity-dependent DNA ligation assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

Bevacizumab and irinotecan for recurrent oligodendroglial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

inferred from DOI database lookup

7 January 2021

based on heuristic

Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumour growth and angiogenesis in human glioblastoma xenografts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25462

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.25462

1 reference

8 February 2018

PubMed ID

20665891

1 reference

8 February 2018